Flavoxate
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682706 |
| ATC code | |
| Identifiers | |
| |
JSmol) | |
SMILES
| |
| |
  (what is this?) (verify) | |
Flavoxate is an
Clinical uses
Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin)(india), Genurin (by Recordati, Italy) in Italy and KSA, Uritac by El Saad company in Syria, under the name Bladderon by Nippon Shinyaku of Japan, or Bladuril in Chile, Utispas ( Apex Pharma) in Nepal.
Flavoxate is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
Side effects
Flavoxate is generally well tolerated, but can potentially cause vomiting, upset stomach, dry mouth or throat, blurred vision, eye pain,[1] and increased sensitivity of the eyes to light.
Contraindications
Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.
References
- PMID 18754848.
Further reading
- Brenner GN (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6.
- Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4.
- "Flavoxate". PubMed Health. U.S. National Library of Medicine, National Institutes of Health.